A Phase II Study to Assess the Efficacy and Safety of Preoperative Chemo With Radiation Therapy for Patients With Borderline Unresectable Adenocarcinoma of the Pancreas

This study is currently recruiting participants.
Verified March 2014 by University of Arkansas
Sponsor:
Information provided by (Responsible Party):
University of Arkansas
ClinicalTrials.gov Identifier:
NCT01240304
First received: November 9, 2010
Last updated: March 6, 2014
Last verified: March 2014

November 9, 2010
March 6, 2014
November 2010
November 2016   (final data collection date for primary outcome measure)
Overall survival, disease-free survival,and recurrence [ Time Frame: An average of 6 years ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01240304 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Phase II Study to Assess the Efficacy and Safety of Preoperative Chemo With Radiation Therapy for Patients With Borderline Unresectable Adenocarcinoma of the Pancreas
A Phase II Study to Assess the Efficacy and Safety of Preoperative Chemotherapy With Radiation Therapy for Patients With Borderline Unresectable Adenocarcinoma of the Pancreas

The purpose of this phase II clinical trial study is to assess the resection rate among subjects who have been initially diagnosed with unresectable or borderline resectable pancreatic adenocarcinoma. This will be done by providing preoperative treatment that will include alternating cycles of chemotherapy and radiotherapy treatment. In addition, this clinical trial will assess the safety of preoperative chemotherapy with radiation therapy for subjects with unresectable or borderline resectable adenocarcinoma of the pancreatic head, assess margin-negative resection rates, disease-free survival, assess overall survival rates, and determine patterns of local and distant recurrence.

The purpose of this phase II clinical trial study is to assess the resection rate among subjects who have been initially diagnosed with unresectable or borderline resectable pancreatic adenocarcinoma. This will be done by providing preoperative treatment that will include alternating cycles of chemotherapy and radiotherapy treatment. In addition, this clinical trial will assess the safety of preoperative chemotherapy with radiation therapy for subjects with unresectable or borderline resectable adenocarcinoma of the pancreatic head, assess margin-negative resection rates, disease-free survival, assess overall survival rates, and determine patterns of local and distant recurrence.

The study population in this clinical trial will consist of untreated subjects 18 years or older who have a histologically or cytologically confirmed diagnosis of unresectable or borderline resectable adenocarcinoma of the pancreatic head. Once the patient has undergone the necessary tests and the tumor has been staged, the principal investigator or co-investigators will determine if the patient is suitable to be inducted in this clinical trial. The course of preoperative treatment in this study will consist of an alternating combination of 6mg/M² of Gemzar for 24 hours and 7.0 Gy of radiation therapy. The subject will undergo one of these therapies alternating daily for a total of 10 days then the subject will be allowed to rest for 4 weeks before undergoing restaging and surgery. After surgery, the subject will then undergo the conventional chemotherapy regimen consisting of 6 cycles of 1000mg/M² of Gemzar over a 30 minute infusion rate.

The primary outcome of this clinical trial is the margin-negative resection rate. This will be determined by the tumor's response to the pre/post-operative treatment so that the tumor can be removed surgically via pancreaticoduodenectomy. Once the subject has completed the treatment as described in the protocol, he/she will continued to be followed to assess survival and patterns of local and distance recurrence. The purpose of this clinical trial will be an attempt to provide subjects with a more hopeful alternative to treatment for a disease that otherwise offers a grim prognosis.

Interventional
Phase 2
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Pancreatic Cancer
  • Drug: Gemcitabine
    The course of preoperative treatment in this study will consist of an alternating combination of 6mg/M² of Gemcitabine for 24 hours and 7.0 Gy (radiation) of radiation therapy. The subject will undergo one of these therapies alternating daily for a total of 10 days then the subject will be allowed to rest for 4 weeks before undergoing restaging and surgery. After surgery, the subject will then undergo the conventional chemotherapy regimen consisting of 6 cycles (1 cycle = 28 days) of 1000mg/M² of Gemcitabine over a 30 minute infusion rate.
    Other Name: Gemzar
  • Radiation: Radiation therapy
    The course of preoperative treatment in this study will consist of an alternating combination of 6mg/M² of Gemcitabine for 24 hours and 7.0 Gy (radiation) of radiation therapy. The subject will undergo one of these therapies alternating daily for a total of 10 days then the subject will be allowed to rest for 4 weeks before undergoing restaging and surgery. After surgery, the subject will then undergo the conventional chemotherapy regimen consisting of 6 cycles (1 cycle = 28 days) of 1000mg/M² of Gemcitabine over a 30 minute infusion rate.
    Other Name: Radiation therapy
  • Procedure: pancreaticoduodenectomy
    Surgery will be planned 28 days (+/- 3 days) after the last dose of chemotherapy. The liver and pancreas will be examined by palpation and inspection. In the absence of metastases, tumor mobilization and surgical resection will be performed with standard surgical technique.
    Other Name: Removal of pancreas
Experimental: Gemcitabine, radiation therapy, surgery
Interventions:
  • Drug: Gemcitabine
  • Radiation: Radiation therapy
  • Procedure: pancreaticoduodenectomy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
20
November 2016
November 2016   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Ages 18 years and above. There will be no upper age restriction.
  2. ECOG performance status ≤ 2. (See Appendix A -ECOG Performance Status Scale).
  3. Cytologic or histologic proof of adenocarcinoma of pancreas.
  4. Adequate renal, and bone marrow function:

    1. Leukocytes >= 3,000/uL
    2. Absolute neutrophil count >= 1,500/uL
    3. Platelets >= 100,000/Ul
    4. Serum creatinine <= 2.0 mg/dL
  5. Hepatic function (endoscopic or percutaneous drainage as needed)

    a. AST (SGOT)/ALT (SGPT) <= 5 X institutional ULN

  6. Borderline resectable pancreatic cancer:

    1. Short segment hepatic artery abutment (< 180° involvement)
    2. Tumor abutment (<180° ) of superior mesenteric artery
    3. Superior mesenteric/portal vein involvement beyond that of a simple resection and reconstruction
    4. Pancreatitis that obscures the determination of vessel involvement and may preclude an otherwise curative operation
  7. Unresectable pancreatic cancer:

    1. Tumors that encase (> 180° involvement) single or multiple arteries and veins (celiac axis, superior mesenteric artery, superior mesenteric/portal vein, hepatic artery)
    2. Occlusion of superior mesenteric/portal vein

Exclusion Criteria:

  1. Infections such as cholangitis, pneumonia, or wound infections that would preclude protocol therapy.
  2. Women with a positive urine or serum pregnancy test are excluded from this study; women of childbearing potential (defined as those who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 consecutive months) must agree to refrain from breast feeding and practice adequate contraception as specified in the informed consent. Adequate contraception consists of oral contraceptive, implantable contraceptives, injectable contraceptives, a double barrier method, or abstinence.
  3. Subjects cannot have known heptic or peritoneal metastases detected by ultrasound (US), CT scan, or laparotomy/laparoscopy prior to treatment.
  4. Subjects with unstable angina or New York Heart Association (NYHA) Grade II or greater congestive heart failure will be excluded (see Appendix B).
  5. Known presence of central nervous system or brain metastases
  6. Subjects with prior radiotherapy to the upper abdomen or liver will be excluded.
  7. Subjects will be excluded if deemed unable to comply with study and/or follow-up procedures.
  8. Subjects with a known hypersensitivity to Gemzar are excluded.
  9. Multiple positive lymph nodes, which will make the radiotherapy treatment volume too large. Peripancreatic involved nodes can be included in the radiotherapy treatment volume if the field of involved nodes is less than 7.5cm.
Both
18 Years and older
No
Contact: Cynthia Walton 501-686-8274 waltoncynthial@uams.edu
Contact: Sandy Annis 501-686-8274 AMAnnis@uams.edu
United States
 
NCT01240304
112748
No
University of Arkansas
University of Arkansas
Not Provided
Principal Investigator: Issam Makhoul, MD University of Arkansas
University of Arkansas
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP